US equities |
META $622.87 ▼-1.22% TSLA $402.62 ▲+2.81% MU $918.42 ▲+1.63% NVDA $216.19 ▲+0.09% SPCX $149.57 ▲+1.82% AMD $549.96 ▲+3.52% SNDK $1,295.00 ▲+3.14% INTC $92.65 ▲+2.41%
FinancialContent

C4 Therapeutics, Inc. - Common Stock (NQ:CCCC)

2.970 -0.010 (-0.34%)
Delayed Quote Updated: 10:02 AM EDT, Oct 27, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about C4 Therapeutics, Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 Next >
News headline image
Which stocks are moving on Monday? ↗
Looking for insights into the US markets in the middle of the day on Monday? Delve into the top gainers and losers of today's session and gain valuable market intelligence. 
Via Chartmill
News headline image
C4 Therapeutics Highlights Recent Achievement in Biogen Collaboration
Development Candidate Targeting IRAK4 Now Progressing Toward Clinical Development 
From C4 Therapeutics, Inc.
Via GlobeNewswire
News headline image
C4 Therapeutics to Present Data from the Phase 1 Trial of Cemsidomide in Multiple Myeloma at the International Myeloma Society (IMS) Annual Meeting
C4T to Host Webcast on September 20, 2025 at 3 pm ET 
From C4 Therapeutics, Inc.
Via GlobeNewswire
News headline image
12 Health Care Stocks Moving In Thursday's Intraday Session ↗
 
Via Benzinga
News headline image
CCCC Revenue Drops 46% ↗
Via The Motley Fool
News headline image
C4 Therapeutics Reports Second Quarter 2025 Financial Results and Recent Business Highlights
From C4 Therapeutics, Inc.
Via GlobeNewswire
News headline image
C4 Therapeutics Reports First Quarter 2025 Financial Results and Recent Business Highlights
From C4 Therapeutics, Inc.
Via GlobeNewswire
News headline image
Which stocks are moving before the opening bell on Thursday? ↗
As we await the opening of the US market on Thursday, let's delve into the pre-market session and discover the top gainers and losers shaping the early market sentiment. 
Via Chartmill
News headline image
C4 Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Recent Business Highlights
From C4 Therapeutics, Inc.
Via GlobeNewswire
News headline image
C4 Therapeutics to Participate in Upcoming March Investor Conferences
From C4 Therapeutics, Inc.
Via GlobeNewswire
News headline image
C4 Therapeutics Announces 2025 Milestones Across Clinical Portfolio of Degrader Medicines Pursuing Targets of High Unmet Need in Oncology
From C4 Therapeutics, Inc.
Via GlobeNewswire
News headline image
C4 Therapeutics to Present at the 43rd Annual J.P. Morgan Healthcare Conference
From C4 Therapeutics, Inc.
Via GlobeNewswire
News headline image
AT&T To Rally More Than 33%? Here Are 10 Top Analyst Forecasts For Thursday ↗
 
Via Benzinga
News headline image
C4 Therapeutics Presents Cemsidomide Phase 1 Data at the American Society for Hematology (ASH) Annual Meeting that Demonstrated Potential to Become Best-in-Class IKZF1/3 Degrader
From C4 Therapeutics, Inc.
Via GlobeNewswire
News headline image
C4 Therapeutics Appoints Accomplished Oncology Executive Steve Hoerter to Board of Directors
From C4 Therapeutics, Inc.
Via GlobeNewswire
News headline image
C4 Therapeutics Announces First Patient Dosed in CFT8919 Clinical Trial
Clinical Development Initiated in Greater China by Partner Betta Pharmaceuticals 
From C4 Therapeutics, Inc.
Via GlobeNewswire
News headline image
C4 Therapeutics to Present Data from the Ongoing Phase 1/2 Trial of Cemsidomide in Multiple Myeloma and Non-Hodgkin’s Lymphoma at the American Society of Hematology (ASH) Annual Meeting
C4T to Host Webcast on Sunday, December 8, 2024 at 2 PM PT (5 PM ET) 
From C4 Therapeutics, Inc.
Via GlobeNewswire
News headline image
C4 Therapeutics Reports Third Quarter 2024 Financial Results and Recent Business Highlights
From C4 Therapeutics, Inc.
Via GlobeNewswire
News headline image
C4 Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
From C4 Therapeutics, Inc.
Via GlobeNewswire
News headline image
C4 Therapeutics Appoints Paige Mahaney, Ph.D., as Chief Scientific Officer and Announces Retirement of Stewart Fisher, Ph.D.
From C4 Therapeutics, Inc.
Via GlobeNewswire
News headline image
C4 Therapeutics Announces Presentations and Participation in 7th Annual Targeted Protein Degradation & Induced Proximity Summit
From C4 Therapeutics, Inc.
Via GlobeNewswire
News headline image
C4 Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
From C4 Therapeutics, Inc.
Via GlobeNewswire
News headline image
C4 Therapeutics Presents Monotherapy Data Demonstrating Proof of Mechanism and Early Evidence of Proof of Concept From Ongoing CFT1946 Phase 1 Trial in BRAF V600 Mutant Solid Tumors at the European Society for Medical Oncology (ESMO) Congress 2024
From C4 Therapeutics, Inc.
Via GlobeNewswire
News headline image
C4 Therapeutics Announces Delivery of Second Development Candidate to Biogen
From C4 Therapeutics, Inc.
Via GlobeNewswire
News headline image
Methanex, Merck And Other Big Stocks Moving Lower In Monday's Pre-Market Session ↗
 
Via Benzinga
News headline image
Why Summit Therapeutics Shares Are Trading Higher By Around 18%; Here Are 20 Stocks Moving Premarket ↗
 
Via Benzinga
News headline image
C4 Therapeutics to Present Preliminary CFT1946 Monotherapy Phase 1 Clinical Data at the European Society for Medical Oncology (ESMO) Congress 2024
From C4 Therapeutics, Inc.
Via GlobeNewswire
News headline image
C4 Therapeutics Appoints Veteran Biotechnology Leader Stephen Fawell, Ph.D. to Board of Directors
From C4 Therapeutics, Inc.
Via GlobeNewswire
News headline image
C4 Therapeutics to Participate in Upcoming September Investor Conferences
From C4 Therapeutics, Inc.
Via GlobeNewswire
News headline image
C4 Therapeutics Announces European Society for Medical Oncology (ESMO) Changed the Previously Accepted CFT1946 Preliminary Phase 1 Abstract to a Proffered Paper Presentation
Investor Webcast Moved to Friday, September 13, 2024 
From C4 Therapeutics, Inc.
Via GlobeNewswire
< Previous 1 2 3 4 5 6 7 Next >